+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Toxicology Drug Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • PDF Icon

    Report

  • 183 Pages
  • April 2024
  • Region: Global
  • TechSci Research
  • ID: 5950400
Free Webex Call
10% Free customization
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

Global Toxicology Drug Screening Market was valued at USD 11.20 Billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 8.50% through 2029. Toxicology drug screening involves the systematic evaluation of potential adverse effects and safety concerns associated with pharmaceutical compounds. It plays a pivotal role in the drug development process by identifying and assessing the toxicity of substances before they advance to clinical trials and, ultimately, market release. According to an article published in the PMC journal in July 2023, various government authorities recommended nonclinical safety studies such as efficacy, biodistribution, and toxicology studies prior to proceeding to First-in-human (FIH) clinical trials for COVID-19 vaccine candidate consisting of a novel product type for which no prior nonclinical and clinical data were available prior. Such instances show that the demand for toxicology testing increased during the pandemic, fueling the market growth, and the studied market is likely to witness growth during the forecast period. The presence of a well-established pharmaceutical industry in the region, the high RD expenditure, the strong presence of major service providers, and the growing trend of outsourcing analytical testing by pharmaceutical and biopharmaceutical companies in the region are several major factors that contribute to the overall market growth. For instance, according to the October 2023 update by OECD, pharmaceutical spending in the United States, Canada, and Mexico was 2.08, 1.72, and 1.34 (% of gross domestic product (GDP)), respectively, in 2020. This shows the high involvement of major players and manufacturers, along with government organizations, in product development. This increase in expenditure is primarily driven by the focus on having the edge over their competitors and the high returns gained on newly developed products.

Key Market Drivers

Rising Incidence of Substance Abuse

The escalating prevalence of substance abuse has become a catalyst for the robust expansion of the Global Toxicology Drug Screening Market. As the incidence of drug misuse continues to surge globally, organizations are increasingly prioritizing stringent measures to ensure a drug-free workplace and maintain public safety. Consequently, the demand for advanced toxicology drug screening solutions has witnessed a substantial upswing. Employers, healthcare providers, and law enforcement agencies are investing in cutting-edge screening technologies to detect and deter substance abuse effectively.

This heightened awareness of the social and economic ramifications of substance abuse has led to a paradigm shift in drug testing practices. Companies specializing in toxicology screening have seized this opportunity to innovate and develop comprehensive testing methodologies that offer accurate and rapid results. The market's growth is further propelled by regulatory initiatives emphasizing mandatory drug screening in various sectors. As stakeholders recognize the critical role of toxicology screening in fostering a drug-free environment, the Global Toxicology Drug Screening Market is poised for continuous expansion, presenting lucrative opportunities for industry players in the foreseeable future.

Growing Awareness of Occupational Health

The burgeoning awareness of occupational health has emerged as a key driver propelling the growth of the Global Toxicology Drug Screening Market. Employers across diverse industries are increasingly cognizant of the profound impact substance abuse can have on workplace safety, productivity, and overall employee well-being. In response to this awareness, there is a growing emphasis on implementing robust toxicology drug screening programs as an integral component of occupational health and safety protocols.

Companies are recognizing the importance of fostering a drug-free workplace environment to mitigate potential risks associated with impaired performance and accidents. This heightened awareness is steering businesses towards investing in advanced drug screening technologies that provide reliable and swift results, aiding in the early detection of substance abuse among employees.

Regulatory bodies and industry standards are reinforcing the importance of regular toxicology screening, prompting organizations to proactively adopt comprehensive testing measures. As the nexus between occupational health and a drug-free workforce becomes increasingly evident, the Global Toxicology Drug Screening Market is experiencing substantial growth, with companies strategically aligning themselves to meet the evolving demands of the market and capitalize on the expanding awareness of the critical role toxicology screening plays in safeguarding occupational health.

Expanding Pharmaceutical and Biotechnology Industries

The robust growth of the Global Toxicology Drug Screening Market is significantly influenced by the expanding pharmaceutical and biotechnology industries. As these sectors continue to advance in research, development, and production, there is a heightened need for rigorous drug testing protocols to ensure the safety and efficacy of pharmaceutical products. The escalating complexity and diversity of compounds being synthesized necessitate advanced toxicology screening methods to assess potential adverse effects accurately.

Pharmaceutical and biotechnology companies are increasingly integrating comprehensive toxicology screening into their drug development processes to comply with regulatory requirements and ensure the release of safe products to the market. The demand for high-throughput and technologically sophisticated screening solutions has surged, driven by the imperative to streamline drug development timelines and enhance efficiency in the face of expanding pipelines. Global pharmaceutical and biotechnology landscape becomes more competitive, organizations are investing in state-of-the-art toxicology screening technologies to maintain a competitive edge and uphold the highest standards of safety. This symbiotic relationship between the growth of the pharmaceutical and biotechnology industries and the demand for advanced toxicology screening solutions positions the Global Toxicology Drug Screening Market as an integral player in supporting the evolving needs of these dynamic sectors.

Key Market Challenges

Increasing Complexity of Drug Formulations

The burgeoning complexity of drug formulations poses a significant hindrance to the growth of the Global Toxicology Drug Screening Market. As pharmaceutical companies develop increasingly intricate and sophisticated drug compounds, traditional toxicology screening methods face challenges in accurately assessing the potential risks and adverse effects associated with these complex formulations. The intricate nature of modern drugs, often involving intricate combinations of active ingredients and intricate delivery systems, complicates the identification and interpretation of toxicological responses.

Conventional screening approaches may struggle to keep pace with the diversity and intricacy of these formulations, leading to potential gaps in safety assessments. The demand for more specialized and advanced toxicology screening methods rises in tandem with the complexity of drug formulations. This necessitates substantial investments in research and development to innovate screening technologies capable of effectively evaluating the safety profile of the latest generation of pharmaceuticals. The impediment presented by the increasing complexity of drug formulations underscores the importance of ongoing innovation within the toxicology screening market. Companies operating in this space must continually adapt their technologies to address the evolving challenges posed by intricate drug compositions, ensuring that safety assessments remain robust and aligned with the intricacies of modern pharmaceutical development.

Rising Costs of Research and Development

The escalating costs of research and development (RD) present a formidable obstacle to the growth of the Global Toxicology Drug Screening Market. As pharmaceutical and biotechnology companies face ever-increasing expenses in bringing new drugs to market, the financial burden associated with exhaustive RD processes has a cascading effect on the toxicology drug screening sector. The need for thorough safety assessments, an integral part of drug development, prompts companies to allocate significant resources to toxicology studies.

The rising costs of RD constrain organizations from freely investing in cutting-edge toxicology screening technologies. Companies may be hesitant to adopt advanced screening methods due to budgetary constraints, hindering the market's growth potential. Moreover, the pressure to optimize RD budgets may lead to compromises in the thoroughness of toxicology assessments, potentially impacting the accuracy and comprehensiveness of safety evaluations.

To overcome this challenge, the toxicology drug screening market must innovate with cost-effective solutions that maintain high standards of accuracy and reliability. Collaborative efforts between stakeholders, regulatory bodies, and technology providers may also be necessary to streamline processes and reduce overall RD expenditures, ensuring that advancements in toxicology screening remain accessible and feasible for the pharmaceutical and biotechnology industries amidst the escalating costs of innovation.

Key Market Trends

Adoption of High-Throughput Screening (HTS) Technologies

The dynamic growth of the Global Toxicology Drug Screening Market is propelled by the widespread adoption of High-Throughput Screening (HTS) technologies. HTS technologies have revolutionized the drug discovery and development process by enabling the rapid screening of many compounds for potential toxicological effects. This increased efficiency is instrumental in accelerating the pace of drug development, reducing costs, and enhancing overall productivity in the pharmaceutical and biotechnology industries. The automation and parallel processing capabilities of HTS technologies allow for the simultaneous assessment of numerous compounds, expediting the identification of potential safety concerns. The scalability of HTS aligns seamlessly with the evolving needs of the industry, accommodating the growing complexity of drug formulations. This adoption of advanced screening methods not only improves the accuracy and reliability of toxicology assessments but also contributes to the development of safer pharmaceutical products.

As the pharmaceutical landscape increasingly recognizes the value of rapid and comprehensive toxicology screening, the Global Toxicology Drug Screening Market is positioned for sustained growth, driven by the continued integration of innovative High-Throughput Screening technologies into drug development pipelines.

Integration of Artificial Intelligence (AI) and Machine Learning (ML)

The integration of Artificial Intelligence (AI) and Machine Learning (ML) stands as a transformative force propelling the growth of the Global Toxicology Drug Screening Market. AI and ML technologies bring unprecedented efficiency and accuracy to toxicology assessments, automating data analysis and interpretation processes. This advanced analytics capability enables the identification of complex patterns and subtle nuances in large datasets, significantly enhancing the precision of safety evaluations.

The real-time processing and learning capabilities of AI and ML algorithms enable continuous improvement in screening methodologies, adapting to evolving drug formulations and emerging safety concerns. These technologies optimize the identification of potential risks, contributing to faster and more informed decision-making in drug development. Additionally, AI and ML facilitate the integration of diverse data sources, such as genomics and proteomics, enriching the depth of toxicological analyses. As the pharmaceutical and biotechnology industries increasingly leverage the power of AI and ML, the Global Toxicology Drug Screening Market experiences a surge in demand for cutting-edge solutions. The synergy between technological innovation and the evolving needs of the market positions AI and ML as key drivers for sustained growth, offering a paradigm shift in the efficiency and effectiveness of toxicology screening processes.

Segmental Insights

Testing type Insights

Based on the Testing type, the In Silico segment is anticipated to witness substantial market growth throughout the forecast period. The ascent of In Silico testing types emerges as a pivotal driver propelling the growth of the Global Toxicology Drug Screening Market. In Silico testing, leveraging computational models and simulations, presents a paradigm shift in toxicology assessments by offering a cost-effective and time-efficient alternative to traditional in vivo and in vitro methods. This innovative approach allows for the virtual prediction of drug behaviour and toxicity, enabling early identification of potential risks and streamlining the drug development pipeline. The scalability and adaptability of In Silico testing to various drug formulations make it particularly attractive in the face of complex and diverse compounds. Its capacity to analyze vast datasets and simulate intricate biological interactions positions it as a valuable tool in predicting toxicological outcomes with high precision. Furthermore, In Silico methods align seamlessly with the industry's commitment to ethical considerations and animal welfare by reducing reliance on animal testing.

As regulatory bodies increasingly acknowledge the reliability of In Silico testing, the Global Toxicology Drug Screening Market is witnessing a surge in demand for these advanced solutions. The cost efficiencies, predictive accuracy, and ethical advantages associated with In Silico testing underscore its pivotal role in shaping the future of toxicology screening, fostering sustained growth in the market.

Application Insights

Based on the Application segment, the Immunotoxicity segment has been the dominant force in the market. The expansion of the Global Toxicology Drug Screening Market is significantly propelled by the critical role of Immunotoxicity applications. Immunotoxicity assessment has gained prominence in drug development as it focuses on evaluating the impact of pharmaceutical compounds on the immune system. With the increasing complexity of drug formulations, there is a growing awareness of the need to thoroughly understand potential immunotoxic effects. Immunotoxicity screening is essential to identify adverse immune reactions early in the drug development process, reducing the risk of unforeseen immunological issues during clinical trials or post-market release. As regulatory agencies intensify scrutiny on immunosafety profiles, pharmaceutical and biotechnology companies are increasingly incorporating comprehensive immunotoxicity testing into their workflows. The heightened demand for immunotoxicity applications within toxicology screening is driven by the industry's commitment to delivering safer and more effective drugs. The ability to assess the potential impact of pharmaceuticals on immune function contributes to a more thorough safety evaluation, enhancing the overall quality and regulatory compliance of drug development programs. Consequently, the Immunotoxicity application segment emerges as a key growth driver in the Global Toxicology Drug Screening Market, aligning with the evolving standards and complexities in modern drug development.

Regional Insights

North America, specifically the Toxicology Drug Screening Market, dominated the market in 2023, primarily due to North America is poised to be a driving force in the growth of the Global Toxicology Drug Screening Market. The region's prominence is attributed to several factors, including the well-established pharmaceutical and biotechnology industries, stringent regulatory frameworks, and a heightened focus on occupational health and safety. The United States houses a robust pharmaceutical sector characterized by significant RD investments and a continual influx of innovative drug formulations. The growing awareness of the impact of substance abuse on workplace productivity and public safety further fuels the demand for advanced toxicology drug screening solutions.

Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), play a pivotal role in shaping industry standards and requirements for safety assessments, driving the adoption of cutting-edge toxicology screening technologies. Additionally, the increasing prevalence of chronic diseases and the aging population in North America contribute to a rising demand for pharmaceuticals, fostering a parallel need for rigorous toxicology evaluations. As North America continues to be at the forefront of technological advancements and regulatory adherence in the healthcare and life sciences sectors, it emerges as a key driver propelling the growth trajectory of the Global Toxicology Drug Screening Market. Companies operating in this region are well-positioned to capitalize on the evolving demands for advanced screening solutions in the pursuit of safer and more effective pharmaceuticals.

In June 2022, Thermo Fisher introduced a novel liquid chromatography-mass spectrometry (LC-MS) system tailored for forensic toxicology. This system aims to support forensic toxicologists, clinical research toxicologists, employee drug testing facilities, and wellness organizations in staying abreast of emerging and illicit drugs.

Report Scope:

In this report, the Global Toxicology Drug Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Toxicology Drug Screening Market, By Testing Type:

  • In Vitro
  • In Vivo
  • In Silico

Toxicology Drug Screening Market, By Product:

  • Instruments
  • Reagents and Consumables
  • Animal Models
  • Software
  • Other Products

Toxicology Drug Screening Market, By Application:

  • Immunotoxicity
  • Systemic toxicity
  • Developmental and Reproductive Toxicity (DART)
  • Endocrine Disruption
  • Other

Toxicology Drug Screening Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Toxicology Drug Screening Market.

Available Customizations:

Global Toxicology Drug Screening market report with the given market data, the publisher offers customizations according to a company's specific needs.


This product will be delivered within 1-3 business days.

Table of Contents

1 Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Toxicology Drug Screening Market Outlook
5.1. Market Size Forecast
5.1.1. By Value
5.2. Market Share Forecast
5.2.1. By Testing Type (In Vitro, In Vivo, In Silico)
5.2.2. By Product (Instruments, Reagents and Consumables, Animal Models, Software, Other Products)
5.2.3. By Application (Immunotoxicity, Systemic toxicity, Developmental and Reproductive Toxicity (DART), Endocrine Disruption, Other)
5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
5.2.5. By Company (2023)
5.3. Market Map
5.3.1 By Testing Type
5.3.2 By Product
5.3.3 By Application
5.3.4 By Region
6. North America Toxicology Drug Screening Market Outlook
6.1. Market Size Forecast
6.1.1. By Value
6.2. Market Share Forecast
6.2.1. By Testing Type
6.2.2. By Product
6.2.3. By Application
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Toxicology Drug Screening Market Outlook
6.3.1.1. Market Size Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share Forecast
6.3.1.2.1. By Testing Type
6.3.1.2.2. By Product
6.3.1.2.3. By Application
6.3.2. Canada Toxicology Drug Screening Market Outlook
6.3.2.1. Market Size Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share Forecast
6.3.2.2.1. By Testing Type
6.3.2.2.2. By Product
6.3.2.2.3. By Application
6.3.3. Mexico Toxicology Drug Screening Market Outlook
6.3.3.1. Market Size Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share Forecast
6.3.3.2.1. By Testing Type
6.3.3.2.2. By Product
6.3.3.2.3. By Application
7. Europe Toxicology Drug Screening Market Outlook
7.1. Market Size Forecast
7.1.1. By Value
7.2. Market Share Forecast
7.2.1. By Testing Type
7.2.2. By Product
7.2.3. By Application
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Toxicology Drug Screening Market Outlook
7.3.1.1. Market Size Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share Forecast
7.3.1.2.1. By Testing Type
7.3.1.2.2. By Product
7.3.1.2.3. By Application
7.3.2. Germany Toxicology Drug Screening Market Outlook
7.3.2.1. Market Size Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share Forecast
7.3.2.2.1. By Testing Type
7.3.2.2.2. By Product
7.3.2.2.3. By Application
7.3.3. United Kingdom Toxicology Drug Screening Market Outlook
7.3.3.1. Market Size Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share Forecast
7.3.3.2.1. By Testing Type
7.3.3.2.2. By Product
7.3.3.2.3. By Application
7.3.4. Italy Toxicology Drug Screening Market Outlook
7.3.4.1. Market Size Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share Forecast
7.3.4.2.1. By Testing Type
7.3.4.2.2. By Product
7.3.4.2.3. By Application
7.3.5. Spain Toxicology Drug Screening Market Outlook
7.3.5.1. Market Size Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share Forecast
7.3.5.2.1. By Testing Type
7.3.5.2.2. By Product
7.3.5.2.3. By Application
8. Asia-Pacific Toxicology Drug Screening Market Outlook
8.1. Market Size Forecast
8.1.1. By Value
8.2. Market Share Forecast
8.2.1. By Testing Type
8.2.2. By Product
8.2.3. By Application
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Toxicology Drug Screening Market Outlook
8.3.1.1. Market Size Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share Forecast
8.3.1.2.1. By Testing Type
8.3.1.2.2. By Product
8.3.1.2.3. By Application
8.3.2. India Toxicology Drug Screening Market Outlook
8.3.2.1. Market Size Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share Forecast
8.3.2.2.1. By Testing Type
8.3.2.2.2. By Product
8.3.2.2.3. By Application
8.3.3. Japan Toxicology Drug Screening Market Outlook
8.3.3.1. Market Size Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share Forecast
8.3.3.2.1. By Testing Type
8.3.3.2.2. By Product
8.3.3.2.3. By Application
8.3.4. South Korea Toxicology Drug Screening Market Outlook
8.3.4.1. Market Size Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share Forecast
8.3.4.2.1. By Testing Type
8.3.4.2.2. By Product
8.3.4.2.3. By Application
8.3.5. Australia Toxicology Drug Screening Market Outlook
8.3.5.1. Market Size Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share Forecast
8.3.5.2.1. By Testing Type
8.3.5.2.2. By Product
8.3.5.2.3. By Application
9. South America Toxicology Drug Screening Market Outlook
9.1. Market Size Forecast
9.1.1. By Value
9.2. Market Share Forecast
9.2.1. By Testing Type
9.2.2. By Product
9.2.3. By Application
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Toxicology Drug Screening Market Outlook
9.3.1.1. Market Size Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share Forecast
9.3.1.2.1. By Testing Type
9.3.1.2.2. By Product
9.3.1.2.3. By Application
9.3.2. Argentina Toxicology Drug Screening Market Outlook
9.3.2.1. Market Size Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share Forecast
9.3.2.2.1. By Testing Type
9.3.2.2.2. By Product
9.3.2.2.3. By Application
9.3.3. Colombia Toxicology Drug Screening Market Outlook
9.3.3.1. Market Size Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share Forecast
9.3.3.2.1. By Testing Type
9.3.3.2.2. By Product
9.3.3.2.3. By Application
10. Middle East and Africa Toxicology Drug Screening Market Outlook
10.1. Market Size Forecast
10.1.1. By Value
10.2. Market Share Forecast
10.2.1. By Testing Type
10.2.2. By Product
10.2.3. By Application
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Toxicology Drug Screening Market Outlook
10.3.1.1. Market Size Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share Forecast
10.3.1.2.1. By Testing Type
10.3.1.2.2. By Product
10.3.1.2.3. By Application
10.3.2. Saudi Arabia Toxicology Drug Screening Market Outlook
10.3.2.1. Market Size Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share Forecast
10.3.2.2.1. By Testing Type
10.3.2.2.2. By Product
10.3.2.2.3. By Application
10.3.3. UAE Toxicology Drug Screening Market Outlook
10.3.3.1. Market Size Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share Forecast
10.3.3.2.1. By Testing Type
10.3.3.2.2. By Product
10.3.3.2.3. By Application
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends Developments
12.1. Recent Development
12.2. Mergers Acquisitions
12.3. Product Launches
13. Global Toxicology Drug Screening Market: SWOT Analysis
14. Porter’s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Agilent Technologies, Inc.
15.1.1. Business Overview
15.1.2. Product Offerings
15.1.3. Recent Developments
15.1.4. Financials (As Reported)
15.1.5. Key Personnel
15.1.6. SWOT Analysis
15.2. Bio-Rad Laboratories, Inc.
15.3. Merck KGa A
15.4. Charles River Laboratories International, Inc.
15.5. Enzo Life Sciences Inc.
15.6. Eurofins Scientific SE
15.7. Danaher Corporation
15.8. Laboratory Corporation of America Holdings
15.9. Promega Corporation
15.10. The Jackson Laboratory
16. Strategic Recommendations17. About the Publisher

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Merck KGaA
  • Charles River Laboratories International, Inc.
  • Enzo Life Sciences Inc.
  • Eurofins Scientific SE
  • Danaher Corporation
  • Laboratory Corporation of America Holdings
  • Promega Corporation
  • The Jackson Laboratory

Table Information